3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
16
Carcinoma, Non-Small-Cell Lung
7
Breast Neoplasms
7
Urinary Bladder Neoplasms
6
Triple Negative Breast Neoplasms
5
Neoplasm Metastasis
5
Gallbladder Neoplasms
5
Cholangiocarcinoma
5
Nasopharyngeal Carcinoma
4
Carcinoma, Transitional Cell
4
Biliary Tract Neoplasms
4
Recurrence
3
Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Lung Neoplasms
3
Ovarian Neoplasms
2
Lymphoma, Non-Hodgkin
2
Carcinoma, Hepatocellular
2
Bile Duct Neoplasms
2
Virus Diseases
1
Urethral Neoplasms
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Malignant Tumor of Pancreas Metastatic to Liver
1
Liver Neoplasms
1
Klatskin Tumor
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Epstein-Barr Virus Infections
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Interventions
valrubicin
2
Oncolytic Virotherapy
1
Mitomycin
1
Interferons
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Carcinoma in Situ
×
Gemcitabine
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled